Short Interest in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Drops By 53.9%

Posted by George Bondi on Jun 3rd, 2026

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Get Free Report) saw a significant decline in short interest in the month of May. As of May 15th, there was short interest totaling 6,135 shares, a decline of 53.9% from the April 30th total of 13,319 shares. Based on an average trading volume of 56,976 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are short sold.

Genenta Science Price Performance

NASDAQ:GNTA traded up $0.55 during trading hours on Tuesday, reaching $2.20. The company had a trading volume of 6,040,808 shares, compared to its average volume of 1,423,996. Genenta Science has a 1-year low of $0.55 and a 1-year high of $10.00. The company has a current ratio of 14.16, a quick ratio of 14.16 and a debt-to-equity ratio of 0.35. The business’s 50 day moving average price is $0.71 and its 200-day moving average price is $1.11.

Genenta Science (NASDAQ:GNTA – Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.28.

Institutional Trading of Genenta Science

Large investors have recently made changes to their positions in the company. Ghisallo Capital Management LLC purchased a new stake in shares of Genenta Science during the fourth quarter worth approximately $482,000. Weiss Asset Management LP purchased a new stake in Genenta Science in the 4th quarter valued at $480,000. Norges Bank purchased a new stake in Genenta Science in the 4th quarter valued at $337,000. Alyeska Investment Group L.P. purchased a new stake in Genenta Science in the 4th quarter valued at $328,000. Finally, Citadel Advisors LLC purchased a new stake in Genenta Science in the 3rd quarter valued at $41,000. 15.13% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genenta Science in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Get Our Latest Analysis on Genenta Science

About Genenta Science

(Get Free Report)

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.